Use of alkaline protein, including nutritional composition, functional food and use thereof

Abstract

The present invention relates to the use of basic protein for non-therapeutic purposes in promoting brain development and health. The present invention also relates to a nutritional composition comprising basic protein and N-acetylneuraminic acid, a functional food comprising the nutritional composition, and the use of the nutritional composition or functional food for non-therapeutic purposes in promoting brain development and health.

Description

Technical Field

[0001] The present invention generally relates to the field of functional foods. Specifically, the present invention relates to the use of basic proteins for non-therapeutic purposes in promoting brain development and health. The present invention also relates to a nutritional composition for promoting brain development and health, including functional foods of the nutritional composition and the use of the nutritional composition or functional foods for non-therapeutic purposes in promoting brain development and health. Background Art

[0002] Newborns require rapid growth and development, especially of the nervous system, with the brain initially growing faster than any other organ or body tissue. By 2 years of age, the brain is approximately 80% of its adult mass. Infants born prematurely or small for gestational age are particularly vulnerable early in life. Advances in reproductive and neonatal technology have increased the proportion of infants born close to gestational age. However, long-term neurodevelopmental outcomes for premature infants remain poor, characterized by lower school achievement, poor attention and hyperactivity disorders, anxiety disorders, and learning difficulties. Rapid brain growth places extreme demands on the supply of precursors and nutrients. Failure to meet full nutritional requirements during this critical period of brain development can have significant consequences for cognitive development.

[0003] Therefore, it is of great significance to seek a natural functional nutrient that can promote brain development and health, especially that can promote brain development in infants and young children. Summary of the invention

[0004] One object of the present invention is to provide the use of basic protein for non-therapeutic purposes (nutrition and health care) in promoting brain development and health, such as improving memory.

[0005] Another object of the present invention is to provide a nutritional composition for promoting brain development and health, such as improving memory.

[0006] Another object of the present invention is to provide a functional food comprising the nutritional composition.

[0007] A further object of the present invention is to provide the use of the nutritional composition or functional food for non-therapeutic purposes (nutrition and health care) in promoting brain development and health, such as improving memory.

[0008] In particular, the present invention is achieved by:

[0009] 1. The use of basic protein for non-therapeutic purposes in promoting brain development and health.

[0010] 2. The use as described in item 1, wherein the promotion of brain development and health comprises at least one of the following: improving memory.

[0011] 3. The use according to any one of items 1 to 2, wherein the promoting brain development and health comprises improving memory.

[0012] 4. The use according to any one of items 1 to 3, wherein the promoting brain development and health comprises: promoting brain development and health of infants, children, adolescents and / or middle-aged and elderly people.

[0013] 5. The use according to any one of items 1 to 4, wherein the basic protein is used in combination with N-acetylneuraminic acid.

[0014] 6. The use according to item 5, wherein the amount of N-acetylneuraminic acid relative to 1 part by mass of the basic protein is 0.001-10.0 parts by mass, preferably 0.005-4.0 parts by mass, preferably 0.010-3.0 parts by mass, preferably 0.015-2.0 parts by mass, preferably 0.062-1.0 parts by mass, preferably 0.125-0.5 parts by mass, preferably 0.125-0.25 parts by mass.

[0015] 7. The use according to any one of items 1 to 6, wherein the basic protein is a milk-derived basic protein.

[0016] 8. The use according to any one of items 1 to 7, wherein the basic protein is milk basic protein.

[0017] 9. The use according to any one of items 1 to 8, wherein the basic protein is bovine colostrum basic protein.

[0018] 10. A nutritional composition comprising basic protein and N-acetylneuraminic acid.

[0019] 11. The nutritional composition according to item 10, which consists of basic protein and N-acetylneuraminic acid.

[0020] 12. The nutritional composition according to any one of items 10 to 11, wherein the amount of N-acetylneuraminic acid relative to 1 part by mass of the basic protein is 0.001-10.0 parts by mass, preferably 0.005-4.0 parts by mass, preferably 0.010-3.0 parts by mass, preferably 0.015-2.0 parts by mass, preferably 0.062-1.0 parts by mass, preferably 0.125-0.5 parts by mass, preferably 0.125-0.25 parts by mass.

[0021] 13. The nutritional composition according to any one of items 10 to 12, wherein the basic protein is a milk-derived basic protein.

[0022] 14. The nutritional composition according to any one of items 10 to 13, wherein the basic protein is milk basic protein.

[0023] 15. The nutritional composition according to any one of items 10 to 14, wherein the basic protein is bovine colostrum basic protein.

[0024] 16. Functional food comprising the nutritional composition according to any one of items 10 to 15.

[0025] 17. The functional food according to item 16, wherein the functional food is in powder form or liquid form.

[0026] 18. The functional food according to any one of items 16 to 17, wherein the functional food is an infant functional food, a children functional food, a teenager functional food, or an adult functional food, such as an infant formula, a baby food, a nutritional or dietary supplement, a children's formula, a children's snack, a pregnant woman's formula milk, or a middle-aged and elderly milk powder.

[0027] 19. The functional food according to any one of items 16 to 18, wherein the nutritional composition is added in an amount such that the mass content of the basic protein is 0.001-20%, preferably 0.01-10%, relative to the total mass of the functional food, and the amount of N-acetylneuraminic acid is 0.010-3.0 mass parts, preferably 0.015-2.0 mass parts, preferably 0.062-1.0 mass parts, preferably 0.125-0.5 mass parts, preferably 0.125-0.25 mass parts relative to 1 mass part of the basic protein.

[0028] 20. Use of the nutritional composition according to any one of items 10 to 15 or the functional food according to any one of items 16 to 19 for non-therapeutic purposes in promoting brain development and health.

[0029] 21. The use according to item 20, wherein the promoting brain development and health comprises at least one of the following: improving memory.

[0030] 22. The use according to any one of items 20-21, wherein said promoting brain development and health comprises improving memory.

[0031] 23. The use according to any one of items 20 to 22, wherein the promoting brain development and health comprises: promoting brain development and health of infants, children, adolescents and / or middle-aged and elderly people. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1A typical diagram of the movement trajectory of zebrafish in the plus maze after being treated with different samples is shown, wherein for the plus maze of each group, the upper middle area is the blue area, the middle middle area is the colorless area, the lower middle area is the yellow area, the middle left area is the red area, the red right area is the green area, and the upper middle area (i.e., the blue area) indicated by the dotted box is the area used for quantification. DETAILED DESCRIPTION

[0033] Unless otherwise specified, the meanings of the technical terms in this specification are the same as those generally understood by those skilled in the art. However, if there is any conflict, the definitions in this specification shall prevail.

[0034] As used herein, the following terms have the following meanings.

[0035] The term "infant" refers to a human between 0 and 6 months of age.

[0036] The term "older infant" refers to persons 6 to 12 months of age.

[0037] The term "young child" refers to a person between 12 and 36 months of age.

[0038] The term "infant" refers to a human aged 0-36 months.

[0039] The term "child" refers to a person aged 3-6 years.

[0040] The term "juvenile" refers to a person aged 7-17 years.

[0041] The term "adult" refers to a person who is 18 years of age or older.

[0042] The term "youth" refers to persons aged 18-40 years.

[0043] The term "adolescent" refers to persons aged 7-40 years.

[0044] The term "middle-aged" refers to persons aged 41-65 years.

[0045] The term "elderly" or "senior citizen" refers to persons over the age of 65 years.

[0046] The term "infant formula functional food" used herein covers infant formula functional food, follow-up infant formula functional food and toddler formula functional food. Generally, infant formula functional food is used as a breast milk substitute from the birth of the baby, follow-up infant formula functional food is used as a breast milk substitute from 6-12 months after the birth of the baby, and toddler formula functional food refers to a breast milk substitute from 12-36 months after the birth of the baby.

[0047] The term "infant formula functional food" refers to a liquid or powdered product made from milk and milk protein products or soybeans and soybean protein products as the main raw materials, with appropriate amounts of vitamins, minerals and / or other ingredients added, and produced and processed only by physical methods. It is suitable for normal infants to eat, and its energy and nutrients can meet the normal nutritional needs of infants aged 0-6 months.

[0048] The term "follow-up infant formula functional food" refers to a liquid or powdered product made from milk and milk protein products or soy and soy protein products as the main raw materials, with appropriate amounts of vitamins, minerals and / or other ingredients added, and produced and processed only by physical methods. It is suitable for older infants, and its energy and nutritional components can meet part of the nutritional needs of normal older infants aged 6-12 months.

[0049] The term "functional food for infant formula" refers to a liquid or powdered product made from milk and milk protein products or soybeans and soybean protein products as the main raw materials, with appropriate amounts of vitamins, minerals and / or other ingredients added, and produced and processed only by physical methods. It is suitable for infants to eat, and its energy and nutrients can meet part of the nutritional needs of normal infants aged 12-36 months.

[0050] The term "breast milk" is to be understood as mother's breast milk or colostrum.

[0051] The term "exclusively breastfed infant or young child" has its usual meaning and refers to an infant who derives a substantial portion of his or her nutrients and / or energy from human breast milk.

[0052] The term "infants / older infants / young children mainly fed with infant formula functional foods" has a common meaning, referring to infants or young children whose nutritional sources of nutrients and / or energy mainly come from infant formula functional foods, older infant milk or growing-up milk produced and processed by physical methods. The term "mainly" refers to at least 50%, such as at least 75%, of those nutrients and / or energy.

[0053] In addition, in the context of the present invention, the term "comprising" or "including" does not exclude other possible elements. The composition of the present invention (including the various embodiments described herein) may comprise, consist of, or consist essentially of the following elements: the basic elements and necessary limitations of the present invention described herein, and any other or optional ingredients, components, or limitations described herein or otherwise as required.

[0054] The individual described in the present invention is applicable to normal humans, and can be an infant and / or an older infant, and / or a toddler, and / or a child, and / or a young person, and / or a middle-aged person, and / or an elderly person.

[0055] Unless otherwise indicated, all percentages are by mass.

[0056] Now the present invention will be described in more detail. It should be noted that the various aspects, features, embodiments, examples and advantages described in the present application may be compatible and / or may be combined together.

[0057] The present invention relates to the non-therapeutic use of basic protein in promoting brain development and health, such as improving memory, a nutritional composition comprising basic protein and N-acetylneuraminic acid, a functional food comprising the nutritional composition, and the non-therapeutic use of the nutritional composition or functional food in promoting brain development and health, such as improving memory.

[0058] The present invention will be described in detail below.

[0059] Uses of basic protein

[0060] In one aspect, the present invention provides the use of basic proteins for non-therapeutic purposes (nutrition and health) in promoting brain development and health, such as improving memory.

[0061] The alkaline protein mentioned in the present invention refers to edible alkaline protein.

[0062] In one embodiment, the basic protein is a milk-derived basic protein, preferably a milk basic protein, and preferably a basic protein derived from bovine colostrum, ie, bovine colostrum basic protein.

[0063] In the present invention, the milk-derived basic protein may be derived from cow's milk and / or goat's milk.

[0064] Milk alkaline protein is made from fresh milk through processes such as defatting, filtration, concentration, removal of acidic proteins such as casein, cationic chromatography, and freeze-drying.

[0065] Colostrum basic protein is a small molecule active peptide made from colostrum, which is sterilized, defatted, centrifuged, casein, α-lactalbumin, β-lactoglobulin removed, microfiltered, ultrafiltered, freeze-dried and other processes. Studies have shown that it can improve the utilization rate of Ca ions, promote osteoblast proliferation, inhibit osteoclast proliferation, and stimulate the secretion of growth factors. More and more companies are beginning to add CBP to their products. The Ministry of Health's Announcement No. 12 of 2009 approved colostrum basic protein as a new resource functional food. Currently, there is no research on its effects on brain development and improvement of memory damage in the existing technology.

[0066] It should be understood that in this application, the term "bovine colostrum" refers to the milk of a cow within 3 days after calving; the term "milk" refers to the general term for milk produced by a cow, which covers "bovine colostrum" and the milk secreted by the cow after "bovine colostrum" (i.e. 3 days after calving), the latter of which covers normal milk (or mature milk) in the usual sense, that is, the milk secreted by the cow 14 days after calving.

[0067] The inventors have found that alkaline protein also has a new function of promoting brain development and health, such as improving memory, which makes up for the market demand for improving brain development function.

[0068] In one embodiment, the promoting brain development and health includes, for example, at least one of the following: improving memory, preferably including improving memory.

[0069] In one embodiment, the promoting brain development and health includes: promoting human brain development and health, including promoting brain development and health of infants, children, adolescents and / or middle-aged and elderly people; and / or promoting animal, especially mammalian brain development and health.

[0070] In one embodiment, the basic protein can be used in an amount of, for example, 0.005-0.8 g / day / kg body weight, for example, 0.01-0.5 g / day / kg body weight, for example, 0.05-0.2 g / day / kg body weight, for example, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, 0.0 40, 0.045, 0.050, 0.055, 0.060, 0.065, 0.070, 0.075, 0.080, 0.085, 0.090, 0.095, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0 .26、0.27、0.28、0.29、0.30、0.31、0.32、0.33、0.34、0.35、0.36、0.37、0.38、0.39、0.40、0.41、0.42、0.43、0.44、0.45、0.46、0.47、0.48、0.49、0.50、0.51、0.52、0.53、0.54、0.55、0 .56, 0.57, 0.58, 0.59, 0.60, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80g / day / kg body weight or the amount of the range limited by any two thereof. For example, for an infant weighing 6kg, the amount of 0.3-1.2g / day can be taken. When basic protein is used in the above amount, it can significantly play a role in promoting brain development and health, such as improving memory.

[0071] In one embodiment, the basic protein can be used alone.

[0072] In one embodiment, basic protein can be used in combination with N-acetylneuraminic acid.

[0073] In one embodiment, the basic protein is used in combination with N-acetylneuraminic acid, and the amount of N-acetylneuraminic acid relative to 1 part by mass of the basic protein can be 0.001-10.0 parts by mass, preferably 0.005-4.0 parts by mass, preferably 0.010-3.0 parts by mass, preferably 0.015-2.0 parts by mass, preferably 0.062-1.0 parts by mass, preferably 0.125-0.5 parts by mass, preferably 0.125-0.25 parts by mass, for example, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.110, 0.111, 0.112, 0.113, 0.114, 0.115 0.015、0.016、0.017、0.018、0.019、0.020、0.021、0.022、0.023、0.024、0.025、0.026、0.027、0.028、0.029、0.030、0.031、0.032、0.033、0.034、0.035、 0.036、0.037、0.038、0.039、0.040、0.041、0.042、0.043、0.044、0.045、0.046、0.047、0.048、0.049、0.050、0.051、0.052、0.053、0.054、0.055、0.056 , 0.057, 0.058, 0.059, 0.060, 0.061, 0.062, 0.063, 0.064, 0.065, 0.066, 0.067, 0.068, 0.069, 0.070, 0.071, 0.072, 0.073, 0.074, 0.075, 0.076, 0.07 7. 0.078, 0.079, 0.080, 0.081, 0.082, 0.083, 0.084, 0.085, 0.086, 0.087, 0.088, 0.089, 0.090, 0.091, 0.092, 0.093, 0.094, 0.095, 0.096, 0.097, 0.0 98, 0.099, 0.100, 0.105, 0.110, 0.115, 0.120, 0.125, 0.130, 0.135, 0.140, 0.145, 0.150, 0.155, 0.160, 0.165, 0.170, 0.175, 0.180, 0.185, 0.190, 0. 195, 0.200, 0.205, 0.210, 0.215, 0.220, 0.225, 0.230, 0.235, 0.240, 0.245, 0.250, 0.255, 0.260, 0.265, 0.270, 0.275, 0.280, 0.285, 0.290, 0.295, 0.300、0.305、0.310、0.315、0.320、0.325、0.330、0.335、0.340、0.345、0.350、0.355、0.360、0.365、0.370、0.375、0.380、0.385、0.390、0.395、0.400、0.405、0.410、0.415、0.420、0.425、0.430、0.435、0.440、0.445、0.450、0.455、0.460、0.465、0.470、0.475、0.480、0.485、0.490、0.495、0.500、0.505、0.510、0.515、0.520、0.525、0.530、0.535、0.540、0.545、0.550、0.555、0.560、0.565、0.570、0.575、0.580、0.585、0.590、0.595、0.600、0.605、0.610、0.615、0.620、0.625、0.630、0.635、0.640、0.645、0.650、0.655、0.660、0.665、0.670、0.675、0.680、0.685、0.690、0.695、0.700、0.705、0.710、0.715、0.720、0.725、0.730、0.735、0.740、0.745、0.750、0.755、0.760、0.765、0.770、0.775、0.780、0.785、0.790、0.795、0.800、0.805、0.810、0.815、0.820、0.825、0.830、0.835、0.840、0.845、0.850、0.855、0.860、0.865、0.870、0.875、0.880、0.885、0.890、0.895、0.900、0.905、0.910、0.915、0.920、0.925、0.930、0.935、0.940、0.945、0.950、0.955、0.960、0.965、0.970、0.975、0.980、0.985、0.990、0.995、1.00、1.05、1.10、1.15、1.20、1.25、1.30、1.35、1.40、1.45、1.50、1.55、1.60、1.65、1.70、1.75、1.80、1.85、1.90、1.95、2.00、2.05、2.10、2.15、2.20、2.25、2.30、2.35、2.40、2.45、2.50、2.55、2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 3.05, 3.10, 3.15, 3.20, 3.25, 3.30, 3.35, 3.40, 3.45, 3.50, 3.55, 3.60, 3.65, 3.70, 3.75, 3.80, 3.85, 3.90, 3.95, 4.00, 4.05, 4.10, 4.15, 4.20, 4.25, 4.30, 4.35, 4.40, 4.45, 4 .50, 4.55, 4.60, 4.65, 4.70, 4.75, 4.80, 4.85, 4.90, 4.95, 5.00, 5.05, 5.10, 5.15, 5.20, 5.25, 5.30, 5.35, 5.40, 5.45, 5.50, 5.55, 5.60, 5.65, 5.70, 5.75, 5.80, 5.85, 5.90, 5.95, 6.00, 6.05, 6.10, 6.15, 6.20, 6.25, 6.30, 6.35, 6 .40, 6.45, 6.50, 6.55, 6.60, 6.65, 6.70, 6.75, 6.80, 6.85, 6.90, 6.95, 7.00, 7.05, 7.10, 7.15, 7.20, 7.25, 7.30, 7.35, 7.40, 7.45, 7.50, 7.55, 7.60, 7.65, 7.70, 7.75, 7.80, 7.85, 7.90, 7.95, 8.00, 8.05, 8.10, 8.15, 8.20, 8.25, 8.30, 8.35, 8.40, 8.45, 8.50, 8.55, 8.60, 8.65, 8.70, 8.75, 8.80, 8.85, 8.90, 8.95, 9.00, 9.05, 9.10, 9.15, 9.20, 9.25, 9.30, 9.35, 9.40, 9.45, 9.50, 9.55, 9.60, 9.65, 9.70, 9.75, 9.80, 9.85, 9.90, 9.95, 10.0, or a range defined by any two of them. When the ratio of basic protein to N-acetylneuraminic acid is within the above range, the effect on promoting brain development and health, such as improving memory, is more significant, and there may be a synergistic effect between the two. .

[0074] In one embodiment, the basic protein can be used in the form of a composition thereof such as a functional food, especially a milk powder. The functional food can be an infant formula functional food (e.g., infant formula functional food, older infant formula functional food, toddler formula functional food) such as an infant formula milk powder (e.g., infant formula milk powder, toddler formula milk powder), baby food supplement, nutrition or dietary supplement, children's formula milk powder, children's snacks, or a pregnant woman's formula milk powder, middle-aged and elderly milk powder.

[0075] In one embodiment, the basic protein is used in the form of a functional food containing the same. Preferably, the total amount of basic protein in the functional food is 0.001-20%, preferably 0.01-10%, for example, it can be 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.15%, 0.20%, 0.25%, 0.30%, 0.35%, 0.40%, 0.45%, 0.50%, 0.55%, 0.60%, 0.65%, 0.70%, 0.75%, 0.80%, 0.85%, 0.90%, 0.91%, 0.92%, 0.93%, 0.94%, 0.95%, 0.96%, 0.97%, 0.98%, 0.99%, 0.100%, 0.110%, 0.120%, 0.130%, 0.140%, 0.150%, 0.160%, 0.170%, 0.180%, 0.190%, 0.210%, 0.220%, 0.230%, 0.240%, 0.250%, 0.300%, 0.350%, 0.400%, 0.450%, 0.5 75%, 0.80%, 0.85%, 0.90%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2% %, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14.0%, 14.1%, 14.2%, 14.3%, 14.4%, 14.5%, 14.6%, 14.7%, 14.8%, 14.9%, 15.0%, 15.1%, 15.2%, 15.3%, 15.4%, 15.5%, 15.6%, 15.7%, 15.8%, 15.9%, 16.0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17. 2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0% by weight, or the range defined by any two of them. When the alkaline protein is used in the above amount, it can significantly play the role of alkaline protein in promoting brain development and health, such as improving memory, while balancing the nutrients required by the human body in all aspects. .

[0076] Nutritional composition

[0077] As described above, basic protein can also be used in combination with N-acetylneuraminic acid. The present inventors have found that when basic protein is used in combination with N-acetylneuraminic acid, the effect of promoting brain development and health, such as improving memory, can be further enhanced, and a synergistic effect may exist in this regard.

[0078] Therefore, in another aspect, the present invention relates to a nutritional composition comprising a basic protein and N-acetylneuraminic acid.

[0079] All the descriptions made above in the use of basic protein also apply here.

[0080] In one embodiment, when basic protein is used in combination with N-acetylneuraminic acid, the amount of N-acetylneuraminic acid can be 0.001-10.0 mass parts, preferably 0.005-4.0 mass parts, preferably 0.010-3.0 mass parts, preferably 0.015-2.0 mass parts, preferably 0.062-1.0 mass parts, preferably 0.125-0.5 mass parts, preferably 0.125-0.25 mass parts, relative to 1 mass part of basic protein, or can be any amount of N-acetylneuraminic acid as described above in the use part of basic protein or the range defined by any two thereof. When the ratio of basic protein to N-acetylneuraminic acid is within the above range, the effect on promoting brain development and health, such as improving memory, is more significant, and there can be a synergistic effect between the two.

[0081] All the above descriptions in the section on the use of basic proteins also apply here.

[0082] Functional Foods

[0083] In another aspect, the present invention also relates to a functional food comprising the nutritional composition. The functional food of the present invention may be in powder form or in liquid form.

[0084] The functional food of the present invention can be a functional food for infants (e.g., functional food for infants, functional food for older infants, functional food for young children), a functional food for children, a functional food for teenagers, or a functional food for adults, such as infant formula milk powder (e.g., infant formula milk powder, toddler formula milk powder), baby food, nutritional or dietary supplements, children's formula milk powder, children's snacks, milk powder for pregnant women, or milk powder for middle-aged and elderly people. In one embodiment, the nutritional composition is added in an amount such that, relative to the total mass of the functional food, the mass content of the basic protein may be 0.001-20%, preferably 0.01-10%, for example, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.15%, 0.20%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.30%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.40%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.50%, 0.51%, 0.52%, 0.53%, 0.54%, 0.55%, 0.56%, 0.57%, 0.58%, 0.59%, 0.60%, 0.61%, 0.62%, 0.63%, 0.64%, 0.65%, 0.66%, 0.67%, 0.68%, 0.69%, 0.70%, 0.71%, 0.72%, 0.73%, 0.74%, 0.75%, 0.76%, 0.77%, .25%, 0.30%, 0.35%, 0.40%, 0.45%, 0.50%, 0.55%, 0.60%, 0.65%, 0.70%, 0.75%, 0.80%, 0.85%, 0.90%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3 .5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14.0%, 14.1%, 14.2%, 14.3%, 14.4%, 14.5%, 14.6%, 14.7%, 14.8%, 14.9%, 15.0%, 15.1%, 15.2%, 15.3%, 15.4%, 15.5%, 15.6%, 15.7%, 15.8%, 15.9%, 16. 0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0% by mass, or a range defined by any two of them.

[0085] In one embodiment, the amount of the nutritional composition added is such that, relative to the total mass of the functional food, the mass content of N-acetylneuraminic acid can be 0.001-10%, preferably 0.005-5%, for example, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 8 0.9%, 0.10%, 0.15%, 0.20%, 0.25%, 0.30%, 0.35%, 0.40%, 0.45%, 0.50%, 0.55%, 0.60%, 0.65%, 0.70%, 0.75%, 0.80%, 0.85%, 0.90%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2. 6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6 .5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, or a range limited by any two of them.

[0086] When the contents of basic protein and N-acetylneuraminic acid in the functional food are within the above range, it can significantly promote brain development and health, such as improving memory, and at the same time can also balance various aspects of nutrition required by the human body.

[0087] In a preferred embodiment, the amount of the nutritional composition added is such that, relative to the total mass of the functional food, the mass content of the basic protein is 0.001-20%, preferably 0.01-10%, or any other value or range within this range as described above for the basic protein, and relative to 1 mass part of colostrum basic protein, the amount of N-acetylneuraminic acid is 0.010-3.0 mass parts, preferably 0.015-2.0 mass parts, preferably 0.062-1.0 mass parts, preferably 0.125-0.5 mass parts, preferably 0.125-0.25 mass parts, or other amounts or ranges mentioned above in the nutritional composition. When the ratio and amount of basic protein to N-acetylneuraminic acid are within the above range or preferred range, the effect of promoting brain development and health, such as improving memory, is more significant, and there may be a synergistic effect in this regard, and at the same time, it can balance the various aspects of nutrition required by the human body. In addition to basic protein and N-acetylneuraminic acid, the functional food may also contain other ingredients, such as other proteins / amino acids, carbohydrates, fats, vitamins, minerals, etc., which are often contained in formula functional foods such as infant formula functional foods such as milk powder.

[0088] Use of nutritional composition or functional food

[0089] In another aspect, the present invention relates to the use of the above-mentioned nutritional composition or the above-mentioned functional food for non-therapeutic purposes (nutrition and health care) in promoting brain development and health, such as improving memory. In one embodiment, the promotion of brain development and health includes, for example, at least one of the following: improving memory.

[0090] In one embodiment, the promoting brain development and health includes: promoting human brain development, including promoting brain development and health of infants, children, adolescents and / or middle-aged and elderly people; and / or promoting animal, especially mammalian brain development and health.

[0091] In one embodiment, the basic protein can be used in an amount of, for example, 0.005-0.8 g / day / kg body weight, for example, 0.01-0.5 g / day / kg body weight, for example, 0.05-0.2 g / day / kg body weight, for example, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, 0.040, 0.041, 0.042, 0.043, 0.044, 0.045, 0.046, 0.047, 0.048, 0.050, 0.051, 0.052, 0.053, 0.054, 0.056, 0.057, 0.058, 0.059, 0.100, 0.111, 0.112, 0.113, 0.114, 0.115 .040、0.045、0.050、0.055、0.060、0.065、0.070、0.075、0.080、0.085、0.090、0.095、0.10、0.11、0.12、0.13、0.14、0.15、0.16、0.17、0.18、0.19、0.20、0.21、0.22、0.23、0.24、0.25、 0.26、0.27、0.28、0.29、0.30、0.31、0.32、0.33、0.34、0.35、0.36、0.37、0.38、0.39、0.40、0.41、0.42、0.43、0.44、0.45、0.46、0.47、0.48、0.49、0.50、0.51、0.52、0.53、0.54、0.55、0 The amount of the basic protein can be, for example, 0.50, 0.56, 0.57, 0.58, 0.59, 0.60, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80 g / day / kg body weight, or the amount of the range limited by any two thereof. For example, for an infant weighing 6 kg, the basic protein can be taken in an amount of, for example, 0.3-1.2 g / day. And relative to 1 mass part of basic protein, the amount of N-acetylneuraminic acid can be 0.001-10.0 mass part, preferably 0.005-4.0 mass part, preferably 0.010-3.0 mass part, preferably 0.015-2.0 mass part, preferably 0.062-1.0 mass part, preferably 0.125-0.5 mass part, preferably 0.125-0.25 mass part, or any other value or scope within the range as described above. When basic protein and N-acetylneuraminic acid are used in an amount within the above range, especially within a preferred range, the effect on promoting brain development and health, such as improving memory, is more significant, there can be synergistic effect between the two, and at the same time, various aspects of nutrition required by the human body can be balanced.

[0092] Example

[0093] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment.It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0094] Animal experiments

[0095] Brain development and improving memory impairment are important public health issues worldwide. Existing models for improving intelligence are still insufficient in terms of efficiency and speed: on the one hand, the in vivo rat model is time-consuming, labor-intensive, inefficient, low-sensitivity, and requires a large amount of compounds; on the other hand, the experimental conditions of the in vitro cell model are harsh, difficult to master and control, and the action link is relatively single, which cannot reflect the comprehensive effects of in vivo experiments.

[0096] The research on zebrafish in intelligence has physiological and genetic basis: as a typical aquatic vertebrate, although the fish brain organization is simple, it has been distinguished into telencephalon, diencephalon, midbrain, hindbrain, rhombomere, etc., and zebrafish can be used for behavioral evaluation of movement, learning, memory, etc. In addition, its main neurotransmitter systems such as cholinergic, dopamine, and norepinephrine have similar functions to mammals. Like humans, zebrafish are diurnal animals, which is one of the reasons why zebrafish have more advantages than traditional rodent laboratory model organisms. Their behavior depends on vision, they have color vision, and their visual physiology is roughly similar to that of mammals. Zebrafish have also been fully studied in various color preference tests (such as blue> red, green and yellow), color recognition learning paradigms, color vision analysis and vision-related disease models (such as ocular albinism and color blindness). Zebrafish is an ideal model animal for the development of cognitive response research on visual signals.

[0097] Therefore, in basic and preclinical research, zebrafish has become an important model organism for studying brain development and diseases, and an important animal model for studying neural effects.

[0098] 1. Experimental Materials

[0099] 1.1. Sample and preparation information

[0100] Colostrum basic protein (hereinafter referred to as CPB): BioNatIn BV, product batch number CBP023502092150, purity 81.13% by weight

[0101] N-acetylneuraminic acid: Jiabiyu Biotechnology (Stock) Co., Ltd., product batch number: 2107021, purity 98.9% by weight

[0102] CBP and N-acetylneuraminic acid were prepared into 2.00 mg / mL stock solutions with standard dilution water and used immediately after preparation.

[0103] Positive control: Edaravone, manufacturer: Shanghai Aladdin Biochemical Technology Co., Ltd., batch number K1820098, item number P109105, yellow powder, stored in a cool and dry place. Prepared into 5.00 mg / mL stock solution with DMSO, stored at -20°C.

[0104] 1.2. Experimental animals

[0105] Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3), bred and provided by our company's fish farming center, the experimental animal use license number is: SYXK (Zhejiang) 2022-0004, and the breeding management complies with the requirements of the international AAALAC certification (certification number: 001458).

[0106] Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 4 days post fertilization (4 dpf) were used for evaluation of the efficacy of the sample in improving memory (inhibiting acetylcholinesterase).

[0107] The conversion method of zebrafish dosage to human dosage for efficacy evaluation can be found in CN 113496071A. Specifically, for a person weighing 60 kg, the zebrafish dosage and the theoretical human dosage can be converted according to the following relationship: zebrafish (mg / L) = [human (g / day) × 1000] / 6.

[0108] 1.3. Instruments, consumables and reagents

[0109] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); 6-well plate (Nest Biotech, China); 96-well plate (NestBiotech, China); multifunctional microplate reader (SPARK, TECAN, Switzerland).

[0110] Dimethyl sulfoxide (DMSO, batch number BCCD8942, Sigma, Switzerland); bisphenol AF (batch number J1925142, Shanghai Aladdin Biochemical Technology Co., Ltd., China); acetylcholinesterase detection kit (batch number 2780462, AATB Bioquest, USA).

[0111] Acetylcholinesterase detection kit: (Manufacturer: AAT Bioquest, USA, batch number 2780462, product number 11400)

[0112] Dopamine kit antibody primary antibody: Tyrosine Hydroxulase Antibody (manufacturer: Immunostar, USA, batch number 1815002, product number 22941)

[0113] Dopamine kit antibody secondary antibody: Rhodamine Red TM -X(RRX)AffiniPure Goat Anti-MouseIgG+IgM(H+L) (Manufacturer: Jackson ImmunoResearch, USA, Lot No. 152015, Catalog No. 115-295-044)

[0114] Multifunctional microplate reader (manufacturer: TECAN, Switzerland, model SPARK).

[0115] 2. Detection Method

[0116] MTC determination

[0117] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, with 30 fish in each well (experimental group). The samples were administered in water (concentrations shown in Table 1-1), and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were administered with bisphenol AF in water to establish a zebrafish memory impairment model. After treatment at 28℃ for 48h, the MTC of the samples on the model zebrafish was measured.

[0118] 2.2. Assisting in improving memory (inhibiting acetylcholinesterase)

[0119] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, with 30 fish in each well (experimental group). The samples were given water-soluble (concentrations are shown in Table 1-2), the positive control was edaravone at a concentration of 5.00μg / mL, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were given bisphenol AF in water-soluble form to establish a zebrafish memory impairment model. After 48h of treatment at 28℃, the acetylcholinesterase assay kit was used to collect data using a multifunctional microplate reader, and the fluorescence value of acetylcholinesterase in zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the inhibitory efficacy of the sample on acetylcholinesterase. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.

[0120] 2.3. Assists in improving memory (dopamine)

[0121] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, with 30 fish in each well (experimental group). The samples were given water-soluble (concentrations are shown in Table 1-2), the positive control was edaravone at a concentration of 5.00μg / mL, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were given bisphenol AF in water-soluble form to establish a zebrafish memory impairment model. After 48h of treatment at 28℃, a dopamine determination kit was used to collect data using a multifunctional microplate reader, and the fluorescence value of dopamine in zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the inhibitory effect of the sample on dopamine. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.

[0122] 2.4. Evaluation of the repair efficacy of cognitive dysfunction (memory impairment)

[0123] Modeling method and principle: Bisphenol AF induces zebrafish to establish a cognitive dysfunction (memory impairment) model. Bisphenol AF, also known as hexafluorobisphenol A, has stronger estrogenic activity than bisphenol A. It can induce apoptosis of hippocampal cell lines and primary neuronal cells, increase intracellular calcium levels, produce reactive oxygen species (ROS), and upregulate mitogen-activated protein kinase, interrupt the normal physiological function of microglia, affect neural signal transduction, and interfere with the expression of transmitter receptors such as 5-HT, DA, GABA and Glu, thereby causing memory dysfunction. BPAF is an endocrine disruptor. Studies have shown that exposure to BPAF can cause delayed development or even death of embryonic and juvenile zebrafish and impair the learning and memory ability of individual zebrafish. Color is an important environmental factor that affects the physiology and behavior of humans and animals, including social, cognitive and emotional responses. Like humans, zebrafish are diurnal animals, which is one of the reasons why zebrafish have more advantages than traditional rodent laboratory model organisms. Their behavior depends on vision, they have color vision, and their visual physiology is roughly similar to that of mammals. Zebrafish have also been well studied in various color preference tests (such as blue>red, green and yellow), color recognition learning paradigms, color vision analysis and vision-related disease models (such as ocular albinism and color blindness). Zebrafish are ideal model animals for the development of cognitive responses to visual signals. After zebrafish are treated with bisphenol AF, the total movement distance of zebrafish in the blue area is reduced and they do not remember blue. After modeling, the sample is given, and by observing the percentage of the total movement distance of the zebrafish in the blue area to the total movement distance of the entire area, it can be evaluated whether the sample has the effect of repairing cognitive dysfunction / memory damage.

[0124] 3. Test results

[0125] MTC determination

[0126] Under the experimental conditions, the maximum detection concentration (MTC) of CBP for improving memory in zebrafish was 2000 μg / mL. See Table 1-1 for details.

[0127] Table 1-1. Results of the maximum detection concentration test for the sample's ability to assist in improving memory (n=30)

[0128]

[0129] 3.2. Assisting in improving memory (inhibiting acetylcholinesterase)

[0130] Under the experimental conditions, CBP has the effect of assisting in improving memory, which is specifically manifested in the inhibition of acetylcholinesterase activity. See Table 1-2 for details.

[0131] Table 1-2. Results of the evaluation experiment on the efficacy of samples in assisting memory improvement (inhibition of acetylcholinesterase) (n=10)

[0132]

[0133] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001

[0134] 3.3. Assisting in improving memory (dopamine)

[0135] Under the conditions of this experiment, CBP has the effect of assisting in improving memory, which is specifically manifested in the promotion of dopamine activity. See Table 1-3 for details.

[0136] Table 1-3. Results of the evaluation experiment on the efficacy of samples in improving memory (dopamine) (n=10)

[0137]

[0138] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001

[0139] 3.4. Evaluation of the repair efficacy of cognitive dysfunction (memory damage)

[0140] Under the experimental conditions, CBP has the function of assisting in improving the repair of memory dysfunction, which is specifically manifested as an increase in the percentage of the total movement distance in the blue area to the total movement distance in the entire area in the cross maze test. See Table 1-4 for details. Figure 1-1 .

[0141] Table 1-4. Results of the experimental evaluation of the efficacy of samples in assisting in improving cognitive dysfunction (n=10)

[0142]

[0143] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001

[0144] In this experiment, zebrafish model animals were used. Zebrafish larvae at 4 days post fertilization (4dpf) were exposed to different concentrations of colostrum basic protein (500, 1000, 2000μg / mL) or 5μg / mL edaravone (positive control drug). A normal control group (normal zebrafish treated with fish water) and a model control group (normal zebrafish treated with bisphenol) were set up at the same time. After 48 hours of treatment at 28℃, acetylcholinesterase and dopamine assay kits were used to collect data using a multifunctional microplate reader to analyze the fluorescence values ​​of acetylcholinesterase and dopamine in zebrafish.

[0145] The experimental results show:

[0146] -Compared with the blank control group, the increase in the fluorescence value of acetylcholinesterase in the model control group (i.e., bisphenol group) indicated that bisphenol AF affected the expression of functional genes related to neuronal differentiation and connection, thereby inducing the disorder of neurotransmitter levels in zebrafish, affecting synaptic plasticity, interfering with the storage and release of neurotransmitters, and causing damage to brain nerves.

[0147] -Compared with the model control group, 500, 1000, and 2000 μg / mL colostrum basic protein treatment can continuously inhibit the fluorescence value of zebrafish acetylcholinesterase, with significant differences, and has a significant effect on improving the level of neurotransmitters. In terms of the inhibition of acetylcholinesterase activity, it can achieve a slightly better effect than the drug treatment with edaravone, and is close to the effect of the normal control group.

[0148] - On the other hand, compared with the model control group, 500, 1000, and 2000 μg / mL colostrum basic protein treatment can continuously increase the increase in dopamine neuron area, with significant differences, indicating that colostrum basic protein can help improve memory. And in terms of dopamine activity, it even achieved a slightly better effect than the drug treatment with edaravone.

[0149] - On the other hand, compared with the model control group, 500, 1000, and 2000 μg / mL colostrum basic protein treatment can continuously increase the percentage of the total movement distance in the blue area to the total movement distance in the entire area, with significant differences, indicating that colostrum basic protein can improve cognitive dysfunction and repair memory damage. And in terms of the proportion of the blue area, it has achieved similar or even better results than the drug treatment with edaravone.

[0150] 2.5. Evaluation of the efficacy of the composition in repairing cognitive dysfunction (memory impairment)

[0151] Under the experimental conditions, the colostrum basic protein and N-acetylneuraminic acid combination has the effect of improving cognitive functional disorders. See Table 1-5 for details.

[0152] Table 1-5. Results of experimental evaluation of the efficacy of the composition in assisting in improving cognitive dysfunction (n=10)

[0153]

[0154] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001

[0155] The results show:

[0156] -Compared with the blank control group, the fluorescence intensity of zebrafish in the model control group (i.e., bisphenol group) was significantly reduced, indicating that bisphenol successfully induced memory impairment in zebrafish.

[0157] -Compared with the model control group, the proportion of blue area in each experimental case was increased, indicating that the combination of these two ingredients can help improve memory disorders and repair memory damage.

[0158] - Compared with Comparative Examples 1-3, it can be seen that when colostrum basic protein (500, 1000, 2000 μg / mL) is used in combination with N-acetylneuraminic acid, comparable or even better effects can be achieved compared with the use of colostrum basic protein alone. As the amount of N-acetylneuraminic acid increases (for example, increased to 62, 124 μg / mL), the effect becomes better, indicating that adding N-acetylneuraminic acid to colostrum basic protein can help further improve memory disorders and repair memory damage.

[0159] The inventors also found that compared with the model control group, when the two were used in combination, they could synergistically reverse the memory damage induced by bisphenol, significantly increase the proportion of blue area, and have an improving effect on memory and cognitive impairment.

[0160] In particular, in terms of the components and amounts used, Experimental Example 1 is equivalent to the combination of Comparative Examples 1 and 4. Relative to the model control group, Example 1, Comparative Examples 1 and 4 increase the blue area by 11.2, 11.3 and -0.8, respectively. The increase in the blue area in Example 1 (11.2) is greater than the sum of the increases in Comparative Examples 1 and 4 (10.5).

[0161] Beneficial effects of the invention: The invention provides research on alkaline proteins (such as colostrum alkaline proteins) in memory development, providing new ideas for the development of functional foods in the future. Alkaline proteins (such as colostrum alkaline proteins) have broad prospects in improving cognitive impairment and promoting brain development and health.

[0162] The above is only an exemplary embodiment of the present invention. It should be noted that, for those skilled in the art, without departing from the inventive concept of the present invention, improvements can be made to the present invention, but these all belong to the protection scope of the present invention.

Claims

1. Use of a composition in preparing a functional food for improving memory, characterized in that: The composition consists of bovine colostrum basic protein and N-acetylneuraminic acid, wherein the amount of N-acetylneuraminic acid is 0.125-0.25 parts by mass relative to 1 part by mass of the bovine colostrum basic protein, and the mass content of the bovine colostrum basic protein is 0.01-10% relative to the total mass of the functional food.

2. The use according to claim 1, characterized in that The improving memory includes improving the memory of infants and young children.

3. The use according to claim 1, characterized in that The improving memory includes improving the memory of children, adolescents and / or middle-aged and elderly people.

4. The use according to claim 1, characterized in that The functional food is powder or liquid.

5. The use according to claim 1, characterized in that The functional food is a functional food for infants and young children.

6. The use according to claim 1, characterized in that The functional food is a functional food for children, a functional food for teenagers or a functional food for adults.

7. The use according to claim 1, characterized in that The functional food is infant formula milk powder.

8. The use according to claim 1, characterized in that The functional food is baby food, children's formula milk powder, children's snacks, pregnant women's milk powder, middle-aged and elderly milk powder or dietary supplements.

Images